CureVac rethinks lead cancer program after posting PD-1 data, limiting future studies to mRNA vaccine combos

2022-11-16
FierceBiotech
疫苗临床2期临床结果信使RNA免疫疗法
CureVac presented data on its immunity activator CV8102 late last week.
CureVac is rethinking development of immunity actCV8102 CV8102 in the wake of the publication of data from a checkpoint inhibitor combination trial, vowing to only consider further clinical studies if the drug candidate is paired with “a defined mRNA cancer vaccine.”
CV8102 is a non-coding, non-capped RNA designed to activCV8102nate and adaptive immunity. The candidate entered the clinic in 2014, when CureVac began testing it in combination with a rabies vaccine. Studies of the RNA prospect in cancer indications gcancererway in 2017 with a trial to evaluate the effect of injecting CV8102 into tumors.
CV8102rman biotech presented data from the completed expansion part of the study late last week. In the 30-subject anti-PD-1 combination cohort, 17% of participants experienced a partirabiesponse. None of the 10 subjects who receivcancer102 as a single agent responded to the RNA candidate. CureVac has revised its plansCV8102he moltumorssince seeing the data.
“In the context of our current strategic focus on the development of novel mRNA-based cancer vaccines, data from the plaPD-1 proof-of-principle studies and parallel progress in the discovery of new tumor-specific antigens will provideCV8102asis for any potential integration of CV8102 into tCureVacority program as a strong immune-modulatory adjunct,” the company wrote. “Further clinical development of CV8102 will only be considered in combination with a defined mRNA cancer vaccine.”
While the new position shuts off the prospect of CureVac establishing CV8102 as an enhcancerof immune checkpoint inhibitors, it leaves the door open to it emerging as an enabler of molecules in the tumorch’s own pipeline.CV8102CV8102
CureVac was once focused on a cancer vaccine, CV9104, but the failure CV8102t candidate in a phimmune checkpoint inhibitorsimmune checkpoint inhibitorsimmune checkpoint inhibitorsck that side of the business. This year, the biotech has moved to reinvigorate its work in the area, inking a research and option agreement with myNEO and buying Frame Cancer Therapeutics.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
机构
适应症
靶点
药物
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。